Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by themagicboxon Jul 12, 2020 12:23pm
312 Views
Post# 31257477

RE:200,000 shares

RE:200,000 sharesThe other correspondents from biopub were definitely impressed by the chief medical officer. They are ALL very bullish, esp after the optics surrounding the insider trading.

Im glad they addressed the LTEs, potential nephro issues (with any NSAID), insider tradng optics, and uplisting head on.

Even biopub threw out $600mil as a valuation of the company (based only on 1 product, ATB346). That puts the share price @~$1.3

Echelon wealth has a low of $1.4, target of $1.7, and a high of $2+. Again based soley on one product, not the platform.

Don't let the FUD fairies persuade you without ample evidence haha. You know who you are, cumster.  


crow27 wrote: is not even worth mentioning no matter who sold it or bought it. Focus on the BIG stuff going forward and there is lots that will be happening very soon. This guy sold shares or I think he sold shares and what he knew and what he did not know means nothing.
Antibe has the goods and that's all that matters, the market will start to price this in soon enough.
Focus on what's ahead and forget the he said she said c rap.
Dan did a great interview and remember he has to be very carefull in how he says things and what he says as he can not let any cats out of the bag yet. But that time will come soon enough.
Dan and the team seem wise enough to know how they want to bring this to a US exchange.
it looks like he knows you need to do certain things and have the right people interested before this would be attempted. From his body language he knows that the stock needs to get over $1.00 before this will happen. Looks like more houses will be following and start to promote the stock.
.40 cents is a gift for all investors. Once we are ready and we transfer to the US exchange things can happen real fast.
I personally thought he gave investors a pretty clear picture of how under valued the stock is and what the plan is to increase the SP.


Bullboard Posts